Navigation Links
New therapy shows promise for fighting treatment-resistant cancer cells
Date:6/16/2008

NEW ORLEANS, La.A gene radiotherapy system that detects and treats cancer cells that are resistant to traditional forms of chemotherapy and radiation showed success in the laboratory and could eventually prove beneficial for cancer patients, according to researchers at SNM's 55th Annual Meeting. The new system targets oxygen-deficient hypoxic cancer cells that have activated a gene known as HIF-1, which ensures the cells' survival and makes them unresponsive to most current treatments.

"These types of cancer cells pose a significant challenge in treating many patients," said June-key Chung, a professor of nuclear medicine at Seoul National University College of Medicine, Seoul, South Korea, and lead researcher of the study, Human NIS Gene Radiotherapy Targeting HIF-1 Activated Cancer Cells. "Our research shows that this system successfully targets these hard-to-treat cells in vitro. Eventually, it could offer a novel way to develop new therapies for drug- and radiation-resistant cancers."

Hypoxic cancer cells are found in solid tumors that develop in many different cancers, including cancers of the liver, breast, prostate and uterus. Solid tumors undergo a multitude of cytogenetic or genetic changes over many years, some of which may resist almost any standard therapy.

"It is well known that hypoxic cancer cells are resistant to chemotherapy and radiotherapy, therefore creating a real dilemma for cancer therapies," said Chung. "Now, we are hopeful that new therapeutic models targeting resistant cancers, which are currently under development in the laboratory, can be successfully used for treatment. The results of our research imply that this is a real possibility."

Hypoxic cancer cells do not develop adequate blood vessels to receive oxygen. Because cells need oxygen to survive, hypoxic cells instead activate the HIF-1 protein, which changes cells' metabolism and enables them to burn sugar for energy without oxygen. Traditional cancer therapies are ineffective against hypoxic cells that have activated HIF-1 because HIF-1 regulates several genes related to the resistance of conventional cancer therapy.

In their research, Chung and his team developed a therapeutic system that targets HIF-1 human liver cancer cells in the laboratory. A reporter gene was developed that would express human sodium iodide symporter (hNIS) in the cancer cells. This gene would simultaneously track the cancer cells and treat them by allowing them to absorb iodine and radioisotope more easily. To improve imaging of the cancer cells even further, researchers also engineered the reporter gene to turn fluorescent when it encountered HIF-1 liver cancer cells so they could be tracked with optical imaging techniques. The reporter gene was then injected into human liver cancer cells. The results indicated that the system not only killed hypoxic liver cancer cells, but also could eventually be useful for visualizing how HIF-1 activation occurs in these cells.


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Modulated radiotherapy can cut treatment time for cancer of the rectum without increasing toxicity
2. Estrogen therapy helps or hurts the brain depending on reproductive status
3. Elekta Launches Web-based Virtual Clinic, Offers Better Understanding of Radiotherapy Solutions for the Treatment of Cancer
4. Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapies
5. Latest research on allergies: Specific immunotherapy can help
6. Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women
7. Breakthrough Isolaz(TM) Acne Therapy Featured in U.S. News & World Report:
8. Solid tumor cells not killed by radiation and chemotherapy become stronger
9. Specialist nurses can play a key role in supporting patients having radiotherapy
10. Majority of U.S. House Supports Repeal of Medicare Therapy Caps
11. Hill-Rom Innovative TotalCare(R) Bariatric Plus Therapy System Receives Gold Medical Device Excellence Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... , ... Valentine’s Day is nearly upon us, and most singles could probably ... flawless hair, and a sparkling personality are all well and good, but if somebody ... home with Rover. (Actually, man’s best friend might not even want to be near ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly ... vein visualization technology should be used to ensure patient safety when placing an ... INS Standards mandate the use of vein visualization technology in patients with difficult ...
(Date:2/12/2016)... ... 12, 2016 , ... According to an article published February 4th ... significant portion of hernia repairs throughout the United States. Commenting on this article, Beverly ... that this trend has not only been expected, but it seems to be a ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , ... , As Winston Churchill said, “Those who don’t learn from history are doomed to ... expect when they come knocking this year. But that takes time. , Take a ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a ... closed for the ISE Southeast Awards 2016. Finalists and winners of the ISE® ... Southeast Executive Forum and Awards Gala on March 15, 2016 at the Westin ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... February 12, 2016 ... vermerkt)   http://www.sedar.com ) und ... abrufbar.    --> http://www.sedar.com ... http://www.telestatherapeutics.com abrufbar.    --> ... heute seinen Konzernabschluss des zweiten Quartals ...
(Date:2/12/2016)...  Memorial Hermann Health System has teamed up with ... bring a one-of-a-kind experience to pediatric patients at ... as 360-degree video and Google Cardboard, Howard was able ... giving the patients and their families an unexpected, and ... on video . Memorial Hermann IRONMAN ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
Breaking Medicine Technology: